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ABSTRACT 56 
Recently two related Streptococcus pyogenes strains with reduced 57 
susceptibility to ampicillin, amoxicillin and cefotaxime, antibiotics commonly used 58 
to treat S. pyogenes infections were reported. The two strains had the same 59 
nonsynonymous (amino acid-substituting) mutation in the pbp2x gene encoding 60 
penicillin-binding protein 2X (PBP2X). This concerning report led us to investigate 61 
our library of 7,025 genome sequences of type emm1, emm28, and emm89 S. 62 
pyogenes clinical strains recovered from intercontinental sources for mutations in 63 
pbp2x. We identified 137 strains that combined had 37 nonsynonymous mutations 64 
in 36 codons in pbp2x. Although to a lesser magnitude than the two previously 65 
published isolates, many of our strains had decreased susceptibility in vitro to 66 
multiple beta-lactam antibiotics. Many pbp2x mutations were found only in single 67 
strains, but 16 groups of two or more isolates of the same emm type had an identical 68 

















amino acid replacement. Phylogenetic analysis showed that with one exception, 69 
strains of the same emm type with the same amino acid replacement were clonally 70 
related by descent. This finding indicates that strains with some amino acid changes 71 
in PBP2X can successfully spread to new human hosts and cause invasive infections. 72 
Mapping of the amino acid changes onto a three-dimensional structure of the 73 
related Streptococcus pneumoniae PBP2X suggests that some substitutions are 74 
located in regions functionally important in related pathogenic bacterial species. 75 
Decreased beta-lactam susceptibility is geographically widespread in strains of 76 
numerically common emm gene subtypes. Enhanced surveillance and further 77 
epidemiological and molecular genetic study of this potential emergent 78 
antimicrobial problem are warranted. 79 
 80 
 81 
KEYWORDS: population genomics, bioinformatics, antibiotic resistance, whole 82 
genome sequencing, public health 83 
 84 
INTRODUCTION 85 
Generations of microbiologists, physicians and others with strong interests in 86 
infectious diseases have been taught that Streptococcus pyogenes (group A 87 
streptococcus, GAS) is universally susceptible to beta-lactam antimicrobial agents 88 
(1). Although the molecular basis for this resilient phenotype is unknown, given the 89 
global disease burden of greater than 700 million cases annually (2), universal 90 
susceptibility to these agents has been fortunate. Recently, Vannice et al. (3) 91 
identified two clonally related and epidemiologically linked strains of rare type 92 

















emm43.4 S. pyogenes that had eight-fold higher MICs for ampicillin and amoxicillin, 93 
and three-fold higher MICs for cefotaxime, indicating decreased susceptibility to 94 
these antibiotics. The two strains had an identical single nonsynonymous (amino 95 
acid- altering) mutation in the pbp2x gene encoding penicillin-binding protein 2X 96 
(PBP2X). This mutation confers a threonine to lysine replacement at amino acid 553 97 
(Thr553Lys), a polymorphism that was not found in susceptible strains of type 98 
emm43.4. The authors suggested that the Thr553Lys replacement may be a first step 99 
toward S. pyogenes evolving resistance to beta-lactam antibiotics. The genomes of 100 
these two strains were sequenced as part of an outbreak investigation being done 101 
by Public Health-Seattle & King County in collaboration with the Centers for Disease 102 
Control and Prevention (CDC). Standard analysis conducted by the CDC GAS genome 103 
sequencing includes identification of features potentially contributing to antibiotic 104 
resistance including PBP2X variants (4). Through this process the pbp2x missense 105 
mutations  associated with decreased antibiotic susceptibility reported by Vannice 106 
et al. were detected. The identification of these two strains is concerning and may 107 
signal a substantial public health problem because beta-lactams remain the frontline 108 
treatment globally for the majority of GAS infections. 109 
 To assess the potentially unrecognized broader extent of this inauspicious 110 
discovery, we felt compelled to interrogate our library of 7,025 S. pyogenes genome 111 
sequences of type emm1, emm28, and emm89 clinical isolates from intercontinental 112 
sources for nonsynonymous mutations in pbp2x. Bioinformatic analysis identified 113 
137 strains with 37 amino acid changes at 36 sites in pbp2x that could alter MIC 114 
values for beta-lactam antibiotics. A subset of strains with pbp2x mutations was 115 

















analyzed for beta-lactam MIC values using the gradient method (Etest strips). Our 116 
results indicate that clinical isolates with pbp2x mutations associated with small 117 
decreases in beta-lactam susceptibility in this common human-specific pathogen are 118 
more widespread than appreciated. Enhanced surveillance and fuller epidemiologic-119 
al and molecular genetic study of this potentially emergent antimicrobial problem 120 
are warranted. 121 
 122 
MATERIALS AND METHODS 123 
 S. pyogenes strains and whole-genome sequence data. The emm1 (n = 124 
3,615), emm28 (n = 2,095), and emm89 (n = 1,315) S. pyogenes strains we studied 125 
have been described in our previous publications (5-8). The genome sequence data 126 
generated with Illumina instruments have been deposited previously in publicly 127 
available databases in the National Center for Biotechnology Information Sequence 128 
Read Archive (Bioprojects: PRJNA236767, PRJNA434389, PRJNA287922, 129 
PRJNA387243). Nucleotide polymorphisms in the pbp2x gene in these strains were 130 
identified by bioinformatics methods that have been extensively described 131 
previously (5). 132 
 133 
 Antibiotic susceptibility determinations. Forty-two strains with 134 
nonsynonymous mutations in pbp2x were tested for potential decreased 135 
susceptibility to penicillin by plating on tryptic soy agar supplemented with 6 ng/ml 136 
penicillin G (benzylpenicillin) or 15 ng/ml ampicillin (9, 10). These strains 137 
represent a diverse array of organisms with distinct pbp2x mutations from emm1, 138 

















emm28, and emm89 organisms. Six reference strains lacking pbp2x mutations (wild-139 
type strains; one strain of emm1, three strains of emm28 and two strains of emm89) 140 
were included as PBP2X consensus wild-type comparators. The reference strains 141 
are emm type- and genetic clade-matched, have the most common allele 142 
representative of their genetic background for global transcriptional regulators of 143 
known virulence factors and several have been extensively studied both in vitro and 144 
in animal virulence experiments. The plates were incubated overnight at 37o C in 145 
5% CO2, and growth was assessed as present or absent. Minimal inhibitory 146 
concentration (MIC) values for six beta-lactam antibiotics (ampicillin, penicillin G, 147 
cefotaxime, cefoxitin, ceftazidime, and meropenem) were determined by the 148 
gradient method (Etest strips, BioMerieux) using standard clinical laboratory 149 
procedures. MIC values were scored independently by three investigators. Some 150 
strains were also tested for penicillin G and ampicillin susceptibility by broth 151 
microdilution in Todd-Hewitt broth supplemented with 0.5% yeast extract (THY). 152 
Liquid cultures were incubated overnight at 37o C in 5% CO2, and growth was 153 
determined by optical density at 600 nm. 154 
 155 
 Phylogenetic analysis of whole genome sequence data. Phylogeny among 156 
the strains was inferred by Neighbor-Joining based on concatenated sequential core 157 
chromosomal SNPs by methods described previously (5). To constrain inferences to 158 
predominantly vertically acquired SNPs, regions of recombination were predicted 159 
based on entire core genome sequences using Gubbins, and putatively horizontally 160 
acquired SNPs were excluded. Clades of related strains were defined using 161 

















hierarchical Bayesian Analysis of Population Structure (hierBAPS), also as 162 
previously described (5). 163 
 164 
Construction of isogenic strain MGAS27213-PBP2X-WT. Isogenic strain 165 
27213-PBP2X-WT was constructed by replacing the naturally-occurring mutant 166 
pbp2x gene (Pro601Leu) of clinical isolate MGAS27213 with the wild-type allele 167 
encoding Pro601 using procedures previously described (11). Briefly, wild-type 168 
pbp2x of strain MGAS27566 was amplified by PCR using primers pbp2x-1 (5’-169 
GTGAATACATGCGATAGGAGAACTCCAG-3’) and pbp2x-2 (5’-170 
CAATTGTACATTGATTCGCCAACTAAGTC-3’). The PCR amplicon was cloned into 171 
suicide vector pBBL740 and then transformed into parental strain MGAS27213, 172 
encoding the mutant pbp2x allele (Pro601Leu). Whole genome sequencing of 173 
isogenic strain MGAS27213-PBP2X-WT confirmed that the mutant pbp2x allele was 174 
replaced by the wild-type pbp2x allele, and the constructed strain lacked spurious 175 
mutations. 176 
 177 
PBP2X structure modeling. The crystal structure of PBP2X from 178 
Streptococcus pneumoniae (PDB: 1RP5, chain A) was used to map the location of the 179 
amino acid substitutions relative to the active site of the transpeptidase domain. 180 
This structure was used because the structure of S. pyogenes PBP2X has not been 181 
determined. The two PBP2X proteins are well conserved in both amino acid 182 
sequence (54.1% identical, 82.1% similar) and structural-fold, and PBP2X from S. 183 
pneumoniae has been well studied by several investigators (12-16). The S. pyogenes 184 

















amino acid substitutions were mapped onto the S. pneumoniae PBP2X structure 185 
using Chimera (17). Chimera was also used to align PBP2X with PBP3 from 186 
Pseudomonas aeruginosa (PDB: 6UN3) and PBP2a from Staphylococcus aureus (PDB: 187 




 Identification of PBP2X amino acid replacements. To test the hypothesis 192 
that S. pyogenes strains in our international collection of human clinical isolates 193 
contained polymorphisms in the pbp2x gene, we interrogated the population 194 
genomic data generated in our previous studies of emm1, emm28, and emm89 195 
organisms (5-8). The vast majority of these strains were recovered from a normally-196 
sterile site of patients with invasive infections such as bacteremia and necrotizing 197 
fasciitis. Among the 7,025 whole genome sequences examined, we identified 137 198 
strains that in the aggregate had 37 nonsynonymous mutations altering 36 codons 199 
of the 2,259-nucleotide pbp2x gene. We also identified 161 strains with a 200 
synonymous single nucleotide polymorphism (that is, a silent mutation that would 201 
not alter the amino acid sequence of PBP2X) at 10 positions, each in a separate 202 
codon of pbp2x. Thus, 79% of SNP sites resulted in an amino acid replacement, a 203 
significantly greater percentage than expected by chance alone (for the 48 pbp2x 204 
alleles in the cohort by the Nei-Gojobori method the ratio of rates of 205 
nonsynonymous/synonymous site substitutions, Ka/Ks = 1.49 with Fisher P-value = 206 
5.27e-41). This elevated percentage of nonsynonymous mutations is consistent with 207 

















the effect of positive selection acting on pbp2x. Among the strains with 208 
nonsynonymous mutations, with a single exception, each of the 137 strains had only 209 
one amino acid replacement relative to the consensus wild-type PBP2X sequence. 210 
The exception was an emm28 strain (MGAS28532) recovered in the United States 211 
that had a unique combination of two contiguous amino acid replacements 212 
(Phe599Tyr and Gly600Asp) in PBP2X (Table 1). Of note, none of the 7,025 isolate 213 
sequences interrogated had an insertion or deletion mutation in pbp2x indicating 214 
that the peptidoglycan transpeptidase function of PBP2X is essential. This finding is 215 
consistent with the results of saturating transposon mutagenesis screens that 216 
during library generation also failed to recover strains with integrations in pbp2x 217 
(18, 19). 218 
 The analysis identified four sites that had the same amino acid replacement 219 
(Gly288Ser, Met342Ile, Gly600Asp, and Pro601Leu) present in multiple emm types 220 
(Fig. 1). In each case, these amino acid replacements were represented among 221 
strains of type emm28 and emm89 (Fig. 1). Additionally, these four replacements 222 
were present among multiple isolates within a single emm type. The finding of the 223 
same replacements in both multiple emm types and in multiple isolates of the same 224 
emm type strongly suggests that these changes have been selected by exposure to 225 
beta-lactam antibiotics. In contrast, there was no example of sharing of amino acid 226 
replacements between type emm1 strains and either emm28 or emm89 strains. 227 
Despite the emm1 cohort comprising the greatest number of isolates (n = 3,615) it 228 
had a lower frequency of nonsynonymous SNP sites (n = 8) than either the emm28 229 
(2,095 isolates and 21 nonsynonymous sites) or emm89 (1,315 isolates and 12 sites) 230 

















cohorts. Moreover, the nonsynonymous SNP sites among the emm1 isolates differ in 231 
distribution compared to the emm28 and emm89 isolates, being among the emm1 232 
isolates somewhat less prevalent in the middle (i.e. the transpeptidase domain) and 233 
more prevalent toward the 3’ end of pbp2x (i.e. the PASTA domains). 234 
An alignment of PBP2X of S. pyogenes, S. pneumoniae, and S. agalactiae shows 235 
that the Gly residue at position 288 and Met residue at position 342 are conserved 236 
among the three species (Fig. 2). Of note Met342 is located in the conserved SxxK 237 
motif containing the transpeptidase activity catalytic Ser residue. 238 
 239 
Phylogenetic analysis of strains of the same emm type with the identical 240 
PBP2X amino acid replacement using whole genome sequence data. We 241 
identified 16 instances in which two or more strains of the same emm type had the 242 
identical amino acid replacement (Table 1 and Fig. 1). In general, strains of the 243 
same emm type with the identical pbp2x nonsynonymous mutation were identified 244 
in only one country, although a few exceptions to this were identified (Table 1 and 245 
see Discussion). We tested the hypothesis that the strains with the same amino acid 246 
change were clonally related. This matter is important to address for public health 247 
and basic science reasons because if these organisms are clonally related it is 248 
unambiguous evidence that they can disseminate successfully to new human hosts 249 
and cause infections. Phylogenetic analysis of whole genome sequence data showed 250 
that with one exception, strains of the same emm type with the identical amino acid 251 
replacement are closely related, likely as a consequence of descent from a common 252 
progenitor (Fig. 3). The one exception is the 22 emm28 strains with a Gly600Asp 253 

















replacement (Fig. 3). These findings indicate multiple independent evolutionary 254 
origins of the Gly600Asp polymorphism, that is, multiple episodes of evolutionary 255 
convergence. We note that the single strain with the combined Phe599Tyr and 256 
Gly600Asp replacement is very closely related to two strains having only the single 257 
Gly600Asp change. This phylogenetic relationship suggests that the Phe599Tyr 258 
amino acid change was acquired (likely by selection) after the Gly600Asp change 259 
occurred in a progenitor. Consistent with this idea, the dual amino acid replacement 260 
strain was isolated in 2006, years after the genetically related emm28 strains with 261 
only the Gly600Asp replacement were initially found. 262 
 263 
Association of PBP2X amino acid replacements with decreased 264 
susceptibility to beta-lactam antibiotics. We next tested the hypothesis that the 265 
PBP2X amino acid replacements are associated with decreased susceptibility to 266 
beta-lactam antibiotics. Strains were streaked onto tryptic soy agar plates 267 
supplemented with 6 ng/ml of penicillin G or 15 ng/ml ampicillin, and the plates 268 
were incubated overnight. These concentrations were previously determined to be 269 
minimally inhibitory for S. pyogenes (9, 10). Wild-type strains that lacked pbp2x 270 
mutations did not grow after overnight incubation in the presence of these beta-271 
lactam antibiotics. In contrast, many strains with pbp2x nonsynonymous mutations 272 
grew well on both antibiotic-containing media, including organisms with Gly288Ser, 273 
Met342Ile, Phe599Tyr plus Gly600Asp, Gly600Asp, and Pro601Leu amino acid 274 
replacements (Table 1, Fig. 1 and Fig. 3). Of note, in contrast to the five strains 275 
with the Pro601Leu replacement, the single emm89 strain (MGAS27308) with the 276 

















Pro601Ser change did not grow in the presence of either antibiotic under the plating 277 
conditions tested. Similarly, none of the 10 emm1 strains representing 8 different 278 
amino acid replacements grew under the antibiotic conditions tested. The data are 279 
consistent with the hypothesis of an association between some naturally occurring 280 
pbp2x mutations and decreased susceptibility to these beta-lactams in some genetic 281 
backgrounds. We next used Etest strips to determine the MICs for penicillin G and 282 
found that many strains with pbp2x mutations had decreased susceptibility to this 283 
agent as tested in this fashion, whereas all 18 wild-type comparator strains lacking 284 
pbp2x mutations were fully susceptible (Table 1). 285 
It is well known that the same PBP2X amino acid replacement can confer 286 
divergent susceptibility phenotypes to different beta-lactam antibiotics. Thus, we 287 
next performed MIC susceptibility testing with five additional beta-lactam 288 
antibiotics (ampicillin, cefotaxime, cefoxitin, ceftazidime and meropenem) using the 289 
Etest gradient method. We found that compared to the wild-type control strains, 290 
many PBP2X mutant strains had reduced susceptibility to one or more beta-lactam 291 
antibiotics (Table 1). The Etest MIC results for penicillin G and ampicillin were 292 
confirmed for some strains using broth microdilution, and penicillin G and 293 
ampicillin agar (Table 1, Fig 4 and supplemental Fig. S1). Of note, strains with the 294 
Pro601Leu amino acid change, which occurs in both emm28 and emm89 strains, had 295 
the highest MIC measurements against all beta-lactam antibiotics tested except 296 
cefoxitin (Table 1). Specifically, the penicillin G MICs of strains with the Pro601Leu 297 
change ranged between 23 ng/ml to 32 ng/ml, approximately 4- to 5-fold higher 298 
than those of strains with the wild-type PBP2X (Table 1). To unambiguously 299 

















demonstrate that the Pro601Leu PBP2X amino acid replacement was responsible 300 
for the altered MICs, we created an isogenic strain containing the wild-type pbp2x 301 
gene in place of the naturally occurring mutant pbp2x allele (encoding Pro601Leu). 302 
As expected, the isogenic Pro601 strain (i.e. PBP2X consensus wild-type engineered 303 
derivative strain) was more susceptible to beta-lactam antibiotics than the naturally 304 
occurring parental Pro601Leu substitution strain (Fig. 4). Also, the strain with both 305 
Phe599Tyr and Gly600Asp amino acid replacements had MIC measurements that 306 
were equal to or greater than strains with only the Gly600Asp change, suggesting 307 
that this dual amino acid replacement may have an additive effect on MICs 308 
 309 
Relative location of amino acid changes in the PBP2X three-dimensional 310 
structure. To assess the potential consequence of the identified amino acid 311 
replacements on PBP2X, we mapped the location of the changes on a crystal 312 
structure available for S. pneumoniae PBP2X (Fig. 5). The structure of this protein 313 
has been well studied by several investigators because of its importance in beta-314 
lactam resistance in this common human pathogen (12-14, 16). The variant amino 315 
acids at positions 342, 599, 600, and 601 mapped to regions known to influence 316 
structure-function relationships (20, 21). This determination of influence was 317 
derived from overlaying PBP2X from S. pneumoniae with the clinically relevant and 318 
structurally similar P. aeruginosa PBP3 (PDB: 6UN3) and S. aureus PBP2a (PDB: 319 
1VQQ, chain A). Recently, it was discovered that residues on the bottom of the D-8 320 
helix of PBP3 are essential in forming an aromatic pocket (20) comprised of Tyr532 321 
and Phe533. This aromatic pocket is key in binding and stabilizing the side-chains of 322 

















beta-lactam antibiotics. In PBP2X, a similar, conserved aromatic pocket is formed 323 
with the neighboring His594 and Tyr595 residues. The amino acid substitutions at 324 
residues 599, 600, and 601 we observed in the clinical S. pyogenes isolates studied 325 
here are located directly above this aromatic pocket (Fig. 5). Substitutions at these 326 
positions may perturb binding interactions between the beta-lactam antibiotic and 327 
PBP2X and thereby decrease the acylation efficiency of the antibiotics leading to 328 
reduced susceptibility. It is noteworthy that the Pro601Leu substitution was 329 
associated with decreased penicillin G susceptibility, but the Pro601Ser substitution 330 
was not. The serine side chain is relatively small and hydrophilic, whereas that of 331 
leucine is larger and hydrophobic, and both differ from proline, a secondary (i.e. an 332 
imino acid) amino acid. Thus, both serine and leucine could potentially perturb the 333 
PBP2X structure and beta-lactam binding interactions but to a different extent, 334 
possibly leading to the differences in susceptibility observed. 335 
Similarly, the Met342Ile substitution is noteworthy because residue 342 is 336 
located directly within the active site pocket of PBP2X near the catalytic Ser337. In 337 
PBP2X, a methionine cluster is conserved within the active site (15). Thus, the 338 
Met342Ile substitution present in the clinical S. pyogenes isolate may disrupt the 339 
conserved methionine cluster and thereby perturb binding and acylation of the 340 
enzyme by beta-lactam antibiotics. Decreased acylation efficiency, in turn, would 341 
explain the reduced beta-lactam susceptibility associated with clinical S. pyogenes 342 
isolates containing amino acid variants at position 342. In contrast, the Gly288Ser 343 
substitution is not located in a position to directly impact substrate binding or 344 
acylation (Fig. 5). Indicative of this, the CD of residue 288 is 17.5 Å from the OJ of 345 

















the catalytic Ser337 in the S. pneumoniae PBP2X structure. Regardless, the 346 
substitution could detrimentally impact enzyme dynamics or stability to alter 347 
function. A more definitive conclusion on how the Gly288Ser substitution alters 348 
enzyme structure and function awaits further work. 349 
 350 
DISCUSSION 351 
Here we report on 137 strains of S. pyogenes from intercontinental sources 352 
that have 37 amino acid replacements at 36 sites in the PBP2X protein, some of 353 
which correlate with decreased susceptibility to beta-lactam antibiotics under the 354 
conditions tested. Importantly, none of the mutations we identified resulted in 355 
resistance in vitro to any of the six beta-lactams studied (as defined by CLSI) and 356 
none approached the level for ampicillin or cefotaxime MICs described for the 357 
PBP2X substitution Thr553Lys. This substitution evidently conferred an MIC at the 358 
CLSI-determined breakpoint for nonsusceptibility to ampicillin. However, isogenic 359 
mutant strains were not constructed to prove the mutant allele of pbp2x was solely 360 
responsible for the altered MIC value. This is an important point, because the two 361 
strains described by Vannice et al. also contain a Ser79Phe amino acid replacement 362 
in the topoisomerase ParC. Substituions in ParC can confer resistance to 363 
fluoroquinolone antibiotics. In principle, substitutions in ParC could produce a 364 
slowed growth phenotype potentially contributing to the altered beta-lactam MICs 365 
observed. As described by Vannice et al., all five emm43.4 strains they analyzed also 366 
have a Thr236Ala amino acid replacement in a gene annotated as “glycoside 367 
hydrolase family 25.” The only known enzymatic activity of the family 25 glycoside 368 

















hydrolases is that of a lysozyme muramidase. Members of this protein family 369 
participate in peptidoglycan remodeling, and thus, in principle the Thr236Ala 370 
substitution might also contribute to the altered beta-lactam MIC. Clearly, much 371 
more work using isogenic mutant strains is required to deconvolute the role of 372 
specific amino acid replacements in these proteins to the observed altered MICs. 373 
Our research was stimulated by the recent description of two clonally related 374 
type emm43.4 S. pyogenes strains with the same Thr553Lys amino acid replacement 375 
in PBP2X associated with altered MICs to beta-lactam antibiotics (3). We note that 376 
the Thr553Lys change likely reflects very recent antimicrobial selection in view of 377 
the described course of treatment of the two host patients. Our work was made 378 
possible in part by the availability of 7,025 genome sequences from geographically 379 
dispersed strains of types emm1, emm28, and emm89 that we previously generated 380 
for molecular pathogenesis, population genomic and epidemiologic purposes. This 381 
unique resource permitted us to rapidly identify strains with mutations in the pbp2x 382 
gene by bioinformatic methods and subsequently assess the beta-lactam 383 
susceptibility phenotypes by standard clinical microbiology methods. Our findings 384 
indicate that decreased beta-lactam susceptibility associated with some PBP2X 385 
amino acid polymorphisms in this pathogen is geographically widespread and has 386 
arisen multiple times independently over many years in contemporary epidemic 387 
clones of serotype emm1, emm28 and emm89 GAS (Fig 2). The data support the 388 
interpretation that the nonsynonymous mutations have been selected by exposure 389 
to beta-lactam antibiotics used during treatment of infections caused by S. pyogenes. 390 
However, inasmuch as S. pyogenes can be carried asymptomatically in the upper 391 

















respiratory tract or other anatomic site, it is also possible that selection occurred 392 
during antibiotic treatment of an asymptomatic carrier for an infection caused by 393 
another organism. The potential for reduced beta-lactam susceptibility to confer an 394 
advantage during human infections (either invasive or non-systemic infection such 395 
as pharyngitis or localized skin and soft tissue infections), or asymptomatic carriage 396 
remains untested. More study is required to address these important issues. 397 
 398 
Examples of convergent evolution. Several examples of convergent 399 
evolution to decreased beta-lactam susceptibility were identified in this analysis. 400 
Four instances of the presence of the same otherwise rare single amino acid 401 
polymorphism in strains of different emm types were found. We identified strains of 402 
emm28 and emm89 with each of the following amino acid replacements: Gly288Ser, 403 
Met342Ile, Gly600Asp, or Pro601Leu. Given that strains of emm28 and emm89 are 404 
very distantly related genetically, the only reasonable interpretation is that these 405 
polymorphisms arose independently as a consequence of convergent evolution, 406 
presumably due to selection following exposure to a beta-lactam antibiotic. 407 
Similarly, the occurrence of the Gly600Asp replacement in some emm28 strains that 408 
have not shared a recent common ancestor serves as another clear example of 409 
convergent evolution in pbp2x. As further evidence of convergent evolution, 410 
Chochua et al. also found the Pro601Leu amino acid change in multiple unrelated 411 
GAS lineages, including emm4 and emm75 isolates containing it as a single amino 412 
acid replacement and emm87 and emm89 isolates containing it in combination with 413 
a second substitution (4). 414 


















Why is there an apparent difference between emm1 strains and emm28 416 
and emm89 strains? The majority of strains we identified with pbp2x 417 
nonsynonymous mutations are either type emm28 or type emm89 subclade 3 418 
organisms. In addition, the linear location of PBP2X amino acid replacements differ 419 
in emm1 compared to the emm28 and emm89 strains. We believe there are several 420 
factors that may contribute to these differences. First, it is important to note that 421 
essentially all emm28 organisms do not produce hyaluronic acid capsule as a 422 
consequence of having an insertion of an adenine nucleotide after nucleotide 219 in 423 
an A-T rich region (7). This single nucleotide insertion severely truncates hasA, 424 
whose gene product is required for capsule biosynthesis. Similarly, emm89 425 
organisms of subclade 3 fail to make hyaluronic acid capsule because they lack the 426 
hasABC operon required for capsule biosynthesis (5, 22). The hyaluronic capsule 427 
among other interactions with the host, contributes to the capacity of S. pyogenes to 428 
resist phagocytosis. It is possible that a relationship exists between inability of a S. 429 
pyogenes strain to produce hyaluronic acid capsule and likelihood of generating a 430 
strain that is extant and has PBP2X amino acid changes that result in decreased 431 
beta-lactam susceptibility. Second, it is possible that the in vivo regulation and/or 432 
expression of pbp2x differ between strains of distinct clonal backgrounds. A third 433 
possibility is that for unknown reasons emm1 strains with PBP2X amino acid 434 
replacements are simply less fit in vivo compared to emm28 and emm89 strains. A 435 
fourth possibility is that the in vivo topology of PBP2X differs between emm1 and 436 
emm28 and emm89 strains, perhaps due to interaction with other currently 437 

















unknown proteins. However, all of these ideas are speculative and require more 438 
study to address these important observations. Finally, we note that the possibilities 439 
described above are not mutually exclusive. 440 
 441 
Relationship of our findings to those reported for other pathogenic 442 
beta-hemolytic streptococci. Strains of Streptococcus agalactiae and Streptococcus 443 
dysgalactiae subsp. equisimilis (SDSE) with decreased susceptibility to beta-lactam 444 
antibiotics have been reported (23-39). In the case of SDSE, four isolates cultured 445 
from the blood of three epidemiologically-associated patients were reported to be 446 
resistant to penicillin and oxacillin (25). Whole genome sequencing identified 447 
nonsynonymous mutations in PBP2X that were thought to be causally involved in 448 
the resistance phenotype. In particular, the investigators identified the occurrence 449 
of Thr341Pro and Gln555Glu amino acid replacements and noted that these two 450 
changes are located close to positions 337, 547 and 557 that are among the more 451 
prevalently found variant sites reported for penicillin-resistant S. pneumoniae. As 452 
described above, we identified decreased susceptibility in S. pyogenes strains with 453 
an amino acid change at position 342 (Met342Ile), and the altered amino acid 454 
reported by Vannice et al. was Thr553Lys (3). 455 
 456 
Public health implications. Our population genomic analysis indicates that 457 
S. pyogenes strains with nonsynonymous mutations in pbp2x are not exceedingly 458 
rare in the emm1, emm28, and emm89 organisms we studied, being present in 459 
approximately 2% of the collection of 7,025 isolates studied. Although this relatively 460 

















low frequency is fortunate, two facts give us pause. First, the great majority of the 461 
isolates we previously characterized by whole-genome sequencing were cultured 462 
from patients with invasive episodes. Given the relative lack of strains causing 463 
pharyngitis in this sample, coupled with the well-documented treatment failures 464 
occurring among individuals with culture-positive S. pyogenes pharyngitis (40-48), 465 
it is possible that analysis of large samples of strains from pharyngitis patients will 466 
identify a different percentage of organisms with pbp2x mutations associated with 467 
altered susceptibility to beta-lactam antibiotics. Second, we identified strains with 468 
PBP2X amino acid changes that are clearly clonally related based on phylogenetic 469 
analysis of whole genome data. For example, we recovered clonally related type 470 
emm28 organisms with the Gly600Asp replacement from patients in Canada and 471 
five different states in the US, indicating that they can successfully disseminate over 472 
geographic distances and cause infections. The same is true for the 27 clonally-473 
related strains of type emm1 with the Asp734Gly change, organisms causing 474 
invasive infections in Denmark, Sweden, and Iceland between 2002 and 2007 475 
(Table 1). Taken together, our findings stress the importance of renewed efforts to 476 
monitor antimicrobial susceptibility rates and values in this pathogen on an ongoing 477 
basis, formulating an efficacious human vaccine against S. pyogenes, and the need for 478 
expanded vaccine efforts, as noted by many (49-51). Importantly, these needs also 479 
were highlighted in the report of a symposium held more than two decades ago 480 
dedicated to the topic of lack of penicillin resistance in S. pyogenes (1). 481 
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What may the future hold? Although some favor the idea that we are not at 483 
the beginning of the end of universal susceptibility of S. pyogenes to beta-lactam 484 
antibiotics (52), we believe there are multiple reasons to be less sanguine in the 485 
long term. First, our data show that several distinct pbp2x mutations associated with 486 
decreased susceptibility occur in S. pyogenes strains of multiple emm types. Second, 487 
in contrast to the otherwise rare emm43.4 strains reported by Vannice et al.(3), we 488 
identified PBP2X amino acid replacements in strains of types emm1, emm28, and 489 
emm89, which in the aggregate are common causes of S. pyogenes pharyngitis and 490 
invasive episodes in many countries. Third, some of the organisms with amino acid 491 
changes are clonally related and have been recovered in multiple geographic 492 
locations, in some cases many years apart. Thus, if strains with PBP2X amino acid 493 
replacements have decreased fitness, at least in some cases the deficit is not 494 
sufficient to prohibit successful dissemination of some clonal progeny to new hosts 495 
and capacity to cause serious human invasive infections. Fourth, exchange of genetic 496 
material between S. pyogenes strains can produce progeny with altered phenotypes 497 
such as enhanced virulence and increased antimicrobial agent resistance. Thus, in 498 
principle, there is a risk of gene flow of a mutant pbp2x gene to a susceptible strain, 499 
a process that could accelerate the spread of decreased susceptibility to beta-500 
lactams or frank resistance in this global human pathogen. 501 
 502 
Concluding comment. To summarize, we used our library of 7,025 S. 503 
pyogenes genome sequences from strains of type emm1, emm28, and emm89 to 504 
identify amino acid-altering mutations in pbp2x. Some of the strains with amino acid 505 

















replacements in PBP2X had decreased susceptibility under the laboratory 506 
conditions tested to some beta-lactam antibiotics, including the commonly used 507 
penicillin G. Although many pbp2x mutations occurred in only one or two strains, we 508 
found that some PBP2X amino acid replacements were present in multiple clonally-509 
related strains causing infections many years apart. Decreased susceptibility to 510 
beta-lactams in S. pyogenes is geographically widespread and exists in strains of 511 
numerically common emm gene subtypes. We recommend increased basic science 512 
and translational research attention be applied to this potentially severe public 513 
health threat. For example, the availability of an efficacious human vaccine against S. 514 
pyogenes pharyngitis would significantly decrease use of beta-lactam antibiotic 515 
agents globally. We believe that for diagnostic laboratories not currently routinely 516 
performing beta-lactam susceptibility testing, it is reasonable to consider doing so, 517 
perhaps by measuring penicillin MIC. 518 
 519 
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[Table and Figures] 729 
TABLE 1 Summary of available data for 137 emm1, emm28, and emm89 S. pyogenes 730 
strains with amino acid replacements in PBP2X. 731 


















Fig. 1. Location of PBP2X amino acid replacements identified among the 7,025 733 
genomes of emm1, emm28, and emm89 clinical isolates. Amino acid replacements 734 
identified in multiple strains are highlighted in yellow, with superscripts denoting 735 
the number of strains. Replacements identified in both emm28 and emm89 strains 736 
are in bold and enclosed in brackets. Replacements associated with reduced 737 
susceptibility to one or more of the beta-lactam antibiotics tested under the in vitro 738 
conditions analyzed are shown in red. The dimerization, transpeptidase and PASTA 739 
domains are indicated. 740 
 741 
 742 
Fig. 2. Aligned streptococcal PBP2X sequences. PBP2X of S. pyogenes strain 743 
MGAS5005 (AAZ51984.1), S. pneumoniae (PBP reference sequence WP_050265832) 744 
and S. agalactiae (PBP reference sequence WP_134808185) were aligned with 745 
ClustalW. To facilitate comparisons, for each species, every tenth amino acid is in 746 
red. Amino acids of the consensus sequence are highlighted to indicate conserved 747 
domains as indicated in the inset, lower right. The three key conserved motifs (SxxK, 748 
SxN and KSGT) of the transpeptidase are shown in red and bold below the aligned 749 
sequences. 750 
 751 
Fig. 3. Genetic relationships among S. pyogenes emm1, emm28, and emm89 clinical 752 
isolates. Phylogenies were inferred by Neighbor-Joining based on core chromosomal 753 
SNPs. Isolates with nonsynonymous SNPs in pbp2x are colored according to the 754 

















amino acid replacements in PBP2X as shown in the insets. Clades of more closely 755 
related strains are shown by shapes (e.g. circles and squares) as indicated. A) 756 
Relationships among 3,615 emm1 strains. B) Relationships among 2,095 emm28 757 
strains. C) Relationships among 1,315 emm89 strains. 758 
 759 
Fig. 4. Beta-lactam antibiotic susceptibility assays. A-B) Shown is growth of emm89 760 
PBP2X wild-type strain MGAS27556 (on plate left) in comparison with PBP2X 761 
Pro601Leu amino acid replacement strain MGAS27316 (on plate right) on medium 762 
supplemented with 6 ng/ml penicillin G (panel A) or 15 ng/ml ampicillin (panel B). 763 
C-D) Graphed is MIC dilution growth of emm1, emm28 and emm89 PBP2X wild-type 764 
and amino acid replacement variant strains in THY broth supplemented with 765 
penicillin G (panel C) or ampicillin (panel D). E-F) Graphed is growth of emm89 766 
PBP2X Pro601Leu replacement strain MGAS27213 and its isogenic PBP2X wild-type 767 
engineered derivative in THY broth supplemented with penicillin G (panel E) or 768 
ampicillin (panel F). All THY broth growth experiments were done in quadruplicate 769 
and the results are given as mean ± SD. Significant differences in growth as 770 
determined by Student's t-test at P < 0.05 are indicated with *. 771 
 772 
Fig. 5. Location of S. pyogenes PBP2X substitutions relative to the X-ray 773 
crystallography structure of PBP2X from S. pneumoniae (PDB: 1RP5, chain A). A) 774 
Variant sites influencing structure-function. Illustrated as spheres on the S. 775 
pneumoniae PBP2X ribbon diagram are the key amino acid replacement sites 776 
associated with reduced beta-lactam susceptibility from the S. pyogenes clinical 777 

















isolates with the relative amino acid positions labeled. Shown in red is the 778 
transpeptidase catalytic serine residue (Spn residue 337 = Spy residue 340). The 779 
amino acids depicted are those of the S. pneumoniae PBP2X. B) All variant sites. The 780 
relative position of all 36 amino acid replacement sites observed among the 7,025 781 
sequenced strains are shown as blue spheres with the catalytic serine shown in red. 782 
C) Aromatic pocket. Illustrated is a surface representation showing the aromatic 783 
pocket proposed to be involved in binding and stabilizing beta-lactam side chains. 784 
The His594 and Tyr595 residues lining the pocket are shown in blue. 785 
 786 
 787 

















TABLE 1. PBP2X amino acid replacement strains (n  = 137) and PBP2X wild-type control strains (n = 18)
Strain (MGAS) emm type Amino acid  change Country Year Capsule Penicillin G agar (a) Ampicillin agar(b) Penicillin G MIC (c) Ampicillin MIC Cefotaxime MIC Cefoxitin MIC Ceftazidime MIC Meropenem MIC
1 2221 1 Wild-type Australia 1998 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006
2 23877 1 Wild-type Canada 2002 positive 0.012* 0.016
3 24791 1 Wild-type Finland 2006 positive 0.012* 0.016
4 7867 28 Wild-type Canada 1991 negative 0.012* 0.016
5 8357 28 Wild-type Finland 1996 negative 0.012* 0.016
6 10778 28 Wild-type Canada 1998 negative 0.012* 0.016
7 10783 28 Wild-type Canada 1998 negative 0.012* 0.016
8 11052 28 Wild-type Finland 2000 negative 0.012* 0.016
9 27961 28 Wild-type United States 2005 negative negative negative <0.016 0.016 0.023 1 0.19 0.006
10 28426 28 Wild-type United States 1999 negative negative negative <0.016 0.016 0.032 1.5 0.19 0.004
11 28737 28 Wild-type United States 2012 negative negative negative <0.016 0.016 0.032 1.5 0.19 0.003
12 28905 28 Wild-type United States 2004 negative 0.012* 0.016
13 23530 89 Wild-type Italy 1997 weak 0.012* 0.016
14 26568 89 Wild-type United States 1996 positive 0.012* 0.016
15 26645 89 Wild-type United States 2009 positive 0.012* 0.016
16 26844 89 Wild-type United States 2008 negative negative negative <0.016 0.016 0.023 1.5 0.19 0.006
17 27545 89 Wild-type Finland 2010 weak 0.012* 0.016
18 27566 89 Wild-type Finland 2011 negative negative negative <0.016 0.016 0.032 1.5 0.19 0.006
19 29554 28 Ile47Val Finland 2004 negative negative negative <0.016 <0.016 0.016 0.75 0.125 0.004
20 29632 28 Ile47Val Finland 2002 negative
21 28315 28 Asp52Gly United States 1998 negative negative negative <0.016 0.016 0.023 1 0.19 0.004
22 28329 28 Asp52Gly United States 1998 negative
23 28433 28 Asp52Gly United States 2003 negative
24 28894 28 Asp52Gly United States 2004 negative
25 31966 28 Thr70Asn Norway 2014 negative
26 5534 1 Gly85Ser Finland 1995 positive negative negative <0.016 <0.016 0.016 1 0.19 0.006
27 5546 1 Gly85Ser Finland 1995 positive
28 5555 1 Gly85Ser Finland 1995 positive
29 5556 1 Gly85Ser Finland 1995 positive
30 28692 28 Ser92Phe United States 2008 negative
31 26637 89 Met171Ile United States 2009 negative
32 26639 89 Met171Ile United States 2009 negative
33 26667 89 Met171Ile United States 2009 positive negative negative <0.016 0.016 0.023 1.5 0.25 0.006
34 29128 28 Ala174Val Finland 2014 negative negative negative <0.016 <0.016 0.012 0.75 0.125 0.003
35 29176 28 Ala174Val Finland 2013 negative
36 29178 28 Ala174Val Finland 2013 negative
37 29316 28 Ala174Val Finland 2010 negative
38 27413 89 Asp233Asn United States 2011 negative
39 29408 28 Thr245Ile Finland 2008 negative negative negative <0.016 <0.016 0.012 0.75 0.125 0.003
40 29254 28 Phe274Leu Finland 2012 negative positive negative 0.016 0.023 0.023 2 0.19 0.006
41 28415 28 Val281Ile United States 2003 negative
42 28772 28 Gly288Ser United States 2012 negative
43 28773 28 Gly288Ser United States 2012 negative positive positive 0.016 0.023 0.032 1.5 0.25 0.006
44 26860 89 Gly288Ser United States 2003 positive positive positive 0.016 0.023 0.047 2 0.38 0.008
45 26929 89 Gly288Ser United States 2003 positive positive positive 0.016 0.023 0.016 1.5 0.19 0.006
46 26932 89 Gly288Ser United States 2003 positive positive positive 0.016 0.023 0.032 1.5 0.25 0.006
47 27438 89 Gly288Ser United States 2006 positive positive positive 0.016 0.023 0.047 1.5 0.25 0.008
48 28711 28 Thr323Met United States 2011 negative
49 10786 28 Met342Ile Canada 1998 negative positive positive 0.016 0.016 0.023 2 0.19 0.004
50 28367 28 Met342Ile United States 2003 negative
51 27033 89 Met342Ile United States 2008 positive positive positive 0.023 0.023 0.032 3 0.25 0.006
52 7898 28 Lys422Arg Canada 1995 negative negative negative <0.016 0.016 0.023 1.5 0.19 0.004
53 7922 28 Lys422Arg Canada 1996 negative
54 7973 28 Lys422Arg Canada 1997 negative
55 10752 28 Lys422Arg Canada 1992 negative

















Strain (MGAS) emm type Amino acid  change Country Year Capsule Penicillin G agar (a) Ampicillin agar(b) Penicillin G MIC (c) Ampicillin MIC Cefotaxime MIC Cefoxitin MIC Ceftazidime MIC Meropenem MIC
56 29061 28 Phe425Leu Finland 2015 negative positive positive 0.016 0.016 0.023 2 0.19 0.006
57 29068 28 Phe425Leu Finland 2015 negative
58 29093 28 Phe425Leu Finland 2014 negative
59 29125 28 Phe425Leu Finland 2014 negative
60 29141 28 Phe425Leu Finland 2014 negative
61 30068 28 Phe425Leu Finland 2015 negative
62 7976 28 Ala438Val Canada 1997 negative positive negative <0.016 0.016 0.023 1.5 0.19 0.006
63 28782 28 Thr461Pro United States 2012 negative positive negative 0.016 0.016 0.016 1.5 0.125 0.006
64 26899 89 Gln462His United States 2003 negative negative negative <0.016 0.016 0.023 1.5 0.19 0.006
65 25070 1 Thr515Aal Norway 2004 positive negative negative <0.016 <0.016 0.016 1 0.125 0.003
66 28088 28 Gly521Ser United States 2010 negative negative negative <0.016 0.016 0.023 1.5 0.19 0.004
67 27590 89 Pro526Leu Finland 2011 negative positive negative <0.016 0.016 0.023 2 0.25 0.006
68 27612 89 Pro526Leu Finland 2012 negative positive negative 0.016 0.016 0.032 2 0.25 0.008
69 23930 1 Thr535Ile Canada 2003 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006
70 28532 28 Phe599Tyr and Gly600Asp United States 2006 negative positive positive 0.023 0.032 0.023 1.5 0.19 0.012
71 7873 28 Gly600Asp Canada 1992 negative
72 7935 28 Gly600Asp Canada 1996 negative
73 7936 28 Gly600Asp Canada 1996 negative
74 7937 28 Gly600Asp Canada 1996 negative
75 7938 28 Gly600Asp Canada 1996 negative
76 7947 28 Gly600Asp Canada 1996 negative
77 7948 28 Gly600Asp Canada 1996 negative
78 7953 28 Gly600Asp Canada 1996 negative
79 7987 28 Gly600Asp Canada 1997 negative
80 7989 28 Gly600Asp Canada 1997 negative
81 7994 28 Gly600Asp Canada 1997 negative
82 8014 28 Gly600Asp Canada 1999 negative
83 8015 28 Gly600Asp Canada 1999 negative
84 8016 28 Gly600Asp Canada 1999 negative
85 10813 28 Gly600Asp Canada 2000 negative
86 27982 28 Gly600Asp United States 2005 negative
87 28165 28 Gly600Asp United States 1998 negative
88 28336 28 Gly600Asp United States 2000 negative
89 28380 28 Gly600Asp United States 2003 negative
90 28425 28 Gly600Asp United States 1999 negative positive positive 0.016 0.023 0.032 1.5 0.19 0.006
91 28792 28 Gly600Asp United States 2000 negative positive positive 0.016 0.023 0.032 1.5 0.19 0.006
92 27143 89 Gly600Asp United States 2012 negative positive positive 0.016 0.023 0.032 1.5 0.125 0.006
93 27326 89 Gly600Asp United States 2013 negative positive positive <0.016 0.016 0.023 1 0.094 0.004
94 29393 28 Pro601Leu Finland 2008 negative positive positive 0.023 0.047 0.047 1.5 0.25 0.012
95 26837 89 Pro601Leu United States 2011 negative
96 27213 89 Pro601Leu United States 2012 negative positive positive 0.032 0.047 0.064 1.5 0.38 0.012
97 27308 89 Pro601Ser United States 2013 negative negative negative <0.016 0.016 0.032 1.5 0.25 0.003
98 27316 89 Pro601Leu United States 2013 negative positive positive 0.032 0.047 0.064 1.5 0.38 0.016
99 27453 89 Pro601Leu United States 2010 negative positive positive 0.032 0.047 0.064 1.5 0.38 0.012
100 31677 89 Asp620Tyr Scotland 2016 negative negative negative <0.016 0.016 0.023 1.5 0.19 0.006
101 23875 1 Arg632His Canada 2002 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006
102 23888 1 Arg632His Canada 2002 positive
103 23904 1 Arg632His Canada 2002 positive
104 23905 1 Arg632His Canada 2002 positive
105 23906 1 Arg632His Canada 2002 positive
106 23950 1 Arg632His Canada 2003 positive
107 23980 1 Arg632His Canada 2003 positive
108 24056 1 Arg632His Canada 2004 positive
109 24141 1 Arg632His Canada 2002 positive
110 24177 1 Arg632His Canada 2002 positive
111 25364 1 Arg632His Sweden 1998 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006

















Strain (MGAS) emm type Amino acid  change Country Year Capsule Penicillin G agar (a) Ampicillin agar(b) Penicillin G MIC (c) Ampicillin MIC Cefotaxime MIC Cefoxitin MIC Ceftazidime MIC Meropenem MIC
112 25387 1 Arg632His Sweden 2000 positive
113 25388 1 Arg632His Sweden 2000 positive
114 28323 28 Gly647Asp United States 2001 negative
115 10792 28 Ser651Gly Canada 1998 negative
116 26743 89 Val662Ile United States 1999 negative
117 24008 1 Arg692Cys Canada 2003 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006
118 24019 1 Arg692Cys Canada 2003 positive
119 24202 1 Arg692Cys Canada 1999 positive
120 24203 1 Arg692Cys Canada 1999 positive
121 24212 1 Arg692Cys Canada 1999 positive
122 24645 1 Arg692Cys Sweden 2009 positive
123 24692 1 Arg692Cys Sweden 2009 positive
124 24709 1 Arg692Cys Sweden 2009 positive
125 25599 1 Glu695Asp United States 2010 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006
126 25603 1 Glu695Asp United States 2010 positive
127 1350 1 Lys708Arg Germany (d) 1984 positive negative negative <0.016 0.016 0.023 1.5 0.19 0.006
128 27009 89 Lys730Arg United States 2007 negative
129 23858 1 Asp734Gly Iceland 2006 positive negative negative 0.016 0.016 0.023 1.5 0.19 0.004
130 25205 1 Asp734Gly Sweden 2005 positive
131 25221 1 Asp734Gly Sweden 2007 positive negative negative 0.016 0.023 0.023 1.5 0.25 0.006
132 26024 1 Asp734Gly Denmark 2002 positive
133 26052 1 Asp734Gly Denmark 2002 positive
134 26055 1 Asp734Gly Denmark 2002 positive
135 26056 1 Asp734Gly Denmark 2002 positive
136 26057 1 Asp734Gly Denmark 2002 positive
137 26059 1 Asp734Gly Denmark 2002 positive
138 26060 1 Asp734Gly Denmark 2002 positive
139 26064 1 Asp734Gly Denmark 2003 positive
140 26071 1 Asp734Gly Denmark 2003 positive
141 26082 1 Asp734Gly Denmark 2003 positive
142 26083 1 Asp734Gly Denmark 2003 positive
143 26085 1 Asp734Gly Denmark 2003 positive
144 26096 1 Asp734Gly Denmark 2003 positive
145 26101 1 Asp734Gly Denmark 2003 positive
146 26109 1 Asp734Gly Denmark 2003 positive
147 26113 1 Asp734Gly Denmark 2004 positive
148 26159 1 Asp734Gly Denmark 2009 positive
149 26197 1 Asp734Gly Denmark 2005 positive
150 26213 1 Asp734Gly Denmark 2006 positive
151 26231 1 Asp734Gly Denmark 2006 positive
152 26267 1 Asp734Gly Denmark 2007 positive
153 26271 1 Asp734Gly Denmark 2008 positive
154 26279 1 Asp734Gly Denmark 2008 positive
155 26290 1 Asp734Gly Denmark 2008 positive
Note:
(a) Penicillin G agar is supplemented with 6 ng/mL of benzylpenicillin.
(b) Ampicillin agar is supplemented with 15 ng/mL of ampicillin.
(c) All anitibiotic MICs are given in ug/ml. Penicillin G ssays were done using strips with 2 dose ranges, standard = 0.016-to-256 ug/ml or  low = 0.002-to-32 ug/ml,  assays done with the low dose range strips are marked with *.
(d) From the German Democratic Republic (former East Germany).
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PBP dimerization domain, pfam03717
PBP transpeptidase domain, pfam00905
PASTA domains, CDD:275384


















His, n = 13
Gly
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Ser, n = 4
Asp
734
Gly, n = 27
Arg
692
Cys, n = 8
Glu
695
Asp, n = 2
A
Genetic relationships among 2,095 S. pyogenes emm28 isolates inferred by
Neighbor-Joining based on 18,544 recombination filtered core chromosomal SNPs.
Subclade 2B
(   ) n = 11
Subclade 1A
(   ) n = 470
Subclade 2A
(   ) n = 564
Subclade 1B
(   ) n = 1050
Asp
52
Gly, n = 4
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288
Ser, n = 2
Ile
47
Val, n = 2
Ala
174
Val, n = 4
Lys
422
Arg, n = 4
Gly
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Asp, n = 22
Met
342
Ile, n = 2
Phe
425
Leu, n = 6
0.001
B
Genetic relationships among 1,315 S. pyogenes emm89 isolates inferred by
Neighbor-Joining based on 9,225 recombination filtered core chromosomal SNPs.
Clade 1
(   ) n = 359
Clade 3
(   ) n = 875
Clade 2
(   ) n = 81
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Ile, n = 3
Pro
601
Leu, n = 4
Pro
526
Leu, n = 2
Gly
600




Genetic relationships among 3,615 S. pyogenes emm1 isolates inferred by
Neighbor-Joining based on 12,355 recombination filtered core chromosomal SNPs.
Clade 1
(   ) n = 172
Clade 2
(   ) n = 3442
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